Is This Mid-Cap Biotech Stock a Buy Now?

In this article:

Kodiak Sciences (NASDAQ: KOD) is a mid-cap biotech business building a drug portfolio focused on retina therapeutics. Kodiak launched its IPO in 2018, and it has been heads down pushing its pipeline through clinical trials since. The global wet AMD market is estimated to have a total addressable market of $10.4 billion by 2024.

Advertisement